News

In a new report entitled “Effect of Macitentan on Hospitalizations: Results From the SERAPHIN Trial,” researchers describe the benefits of a Macitentan 10 mg dose in reducing the risk for hospitalization in patients with symptomatic pulmonary arterial hypertension. The report was published in the journal of…

Courtesy of EchoSense A recent review on imaging of pulmonary vascular disease and the right ventricle by non-invasive techniques in the context of pulmonary arterial hypertension (PAH) was published in the Canadian Journal of Cardiology. The review entitled “Advanced imaging tools rather…

A French research team was able to demonstrate nebivolol’s beneficial effects in treating pulmonary arterial hypertension (PAH), suggesting that new clinical studies should be conducted to further test the drug. The study entitled: “Nebivolol for Improving Endothelial Dysfunction, Pulmonary Vascular Remodeling, and Right Heart Function in Pulmonary Hypertension”…

Giving a Voice to Pulmonary Hypertension: First Entertainment Credit Union Features #PHAware Advocates Steve and Lucas Van Wormer (PRNewsFoto/First Entertainment Credit Union) Lucas Van Wormer, a thirteen-year-old voice actor with PH working at Cartoon Network, along with his father, partnered with a credit union to raise awareness for pulmonary…

A recent systematic review titled “Pregnancy and pulmonary arterial hypertension: A clinical conundrum,” highlights that pulmonary arterial hypertension (PAH) is an absolute contraindication for pregnant women. Pulmonary arterial hypertension (PAH) is a rare condition that causes progressive increases in pulmonary arterial pressure and pulmonary…

Patients with pulmonary hypertension who require a lung transplant are expected to move to higher priority on the wait list for a life-saving organ. On February 19, the Lung Allocation System, which is a means of prioritizing patients in need of a lung transplant, was…

According to a recent study published in the journal Heart, RV afterload increases in patients with chronic thromboembolic pulmonary hypertension (CTEPH) during exercise, resulting in a marked reduction in RVEF and SV reserve. However, sildenafil may reverse this effect. In patients with…

Albuquerque-based Respira Therapeutics, Inc. is a biopharmaceutical company currently developing a dry powder inhaler drug delivery technology called AOS-DPI for RT234, a drug that is being designed to address pulmonary hypertension and other respiratory diseases such as IPF and COPD. In an effort to bolster the company’s commercialization efforts, they recently announced that Andy Clark has been appointed…

Results of a new study are shedding light on the emotional and physical impact that IPF has on both patients and caregivers. The new insights could help pave the way for improved patient care, leading to better quality of life for those with the disease. Idiopathic…

Specialty pharmaceutical company SteadyMed Ltd. recently raised $12.2 million in equity financing, co-led by subsidiaries of Federated Investors Inc. and Deerfield Management Company L.P., as well as existing shareholders from the company. The funding will be invested in SteadyMed’s therapeutic product candidates for the treatment of orphan diseases, including…

Researchers at the School of Medicine at Sapienza University of Rome found that Concentric hypertrophy in the heart right ventricle might represent a favorable adaptive pattern to increased afterload in idiopathic pulmonary arterial hypertension. The study, entitled “Right ventricular remodeling in idiopathic pulmonary arterial hypertension: adaptive versus…

The ERS Pulmonary Hypertension Research Award will grant €40,000 to a pair of carefully selected scientists currently pursuing active research projects in the field of pulmonary hypertension, with regard to its pathophysiology, basic science, epidemiology, clinical practice, prevention, treatment, diagnosis or rehabilitation. The awards are reserved exclusively for candidates younger than 45 years old at the time…